A Design of Experiments for Tablet Compression - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
A Design of Experiments for Tablet Compression
The author prepared and analyzed a detailed design of experiments for the manufacture of a simple tablet formulation. The aim was to test whether tablet hardness and weight could be controlled during the compression process by adjusting certain machine parameters.
Sep 2, 2011
By: Matthew N. Bahr
Pharmaceutical Technology
Volume 35, Issue 9
« Previous
12345678
Next »

Experimental process and screening-study results


Table I: Results of the screening study for the design envelop for manufacturing a simple tablet formulation.
Once pretrial experiments were completed, a broad design envelope was established using the five factors previously defined. A screening study was designed using a 25–1 -level fractional factorial approach, which produced 16 experiments, as opposed to a full factorial experimental design, which would require 32 experiments. Although only 16 experiments were performed in the screening study, the fractional factorial design produces the same resolution as the full factorial design. In addition to reducing time and material, this 25–1 fractional factorial design tests for interactions between each of the five factors. For the screening study, three centerpoint experiments were added to the design to test for nonlinearity (i.e., curvature in the data) and to help determine whether there was a significant lack of fit to the resulting model equation. Centerpoint experiments set all five factors to their midpoint between the low and high limits.


Table II: Analysis of variance for factorial model according to tablet hardness.
The screening study data is shown in various tables. Table I shows the design summary, Table II shows the analysis of variance (ANOVA) for tablet hardness, and Table III shows the ANOVA for tablet weight. All experimental run data was entered into Design-Ease software (Stat-Ease) for analysis.

« Previous
12345678
Next »

ADVERTISEMENT

blog comments powered by Disqus
About the Author

Matthew N. Bahr

Articles by Matthew N. Bahr
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Featured Jobs

More Jobs
Source: Pharmaceutical Technology, 9/2/2011
 Click here